Our Technology

Uncovering a Universe of Novel Targets

Discovering new targets

For the past few decades, research has relied on omic data to identify novel targets

Conventional target discovery approaches require targets to be mutant, overexpressed, or otherwise non-native to be detectable. This has bottlenecked targeted therapies to the same target families for cancer treatment.

80%

of drugs fail in the clinic due to Toxicity and Efficacy

Overlap between diseased and healthy targets often cause unwanted side effects, leading to failure in clinical trials

9

assets per target

Many approaches for oncology treatment focus on the same well-known targets, creating a crowded and highly competitive landscape and limited treatment options for patients.

Discovering new targets

For the past few decades, research has relied on omic data to identify novel targets

80%

of drugs fail in the clinic due to Toxicity and Efficacy

Overlap between diseased and healthy targets often cause unwanted side effects, leading to failure in clinical trials

9

assets per target

Many approaches for oncology treatment focus on the same well-known targets, creating a crowded and highly competitive landscape and limited treatment options for patients.

Discovering new targets

For the past few decades, research has relied on omic data to identify novel targets

80%

of drugs fail in the clinic due to Toxicity and Efficacy

Overlap between diseased and healthy targets often cause unwanted side effects, leading to failure in clinical trials

9

assets per target

Many approaches for oncology treatment focus on the same well-known targets, creating a crowded and highly competitive landscape and limited treatment options for patients.

Our Technology

Our Rover Target Discovery platform identifies highly-specific novel targets that are invisible to any current approach

We're tackling cancer with a new approach by using structural surfaceomics to identify disease-specific, pathologic protein structures that are not limited to mutant or overexpressed proteins. By precisely targeting the unique regions of these targets, we create first-in-class biologics designed for maximum impact.

Our Technology

Our Rover Target Discovery platform identifies highly-specific novel targets that are invisible to any current approach

Our Technology

Our Rover Target Discovery platform identifies highly-specific novel targets that are invisible to any current approach

01

Patient Derived Models

Matched samples sourced from both healthy and diseased tissues to create patient- derived in vitro models

Healthy Person

Healthy Person

Healthy Person

Cancer Patient

Cancer Patient

Cancer Patient

02

SPC Platform

Advanced Computation

Our computer powers high-throughput structural analysis, identifying disease- specific SPC targets with unparalleled precision, automation, and scalability for drug discovery.

Al + Machine Learning

MD Simulations

Molecular Docking

Empirical Structure Data

Proprietary, Ultra Rapid, High-Sensitivity, Mass Spectrometry-Based Structural Proteomics Technology: Structural Proteomics, Mass Spectrometry.

Structural Proteomics

Mass Spectrometry

03

Identification of Conformational Target

Identification of structural features or epitopes that are unique to the disease state. These are often located on surface proteins and are vital for differentiating between diseased and healthy tissues.

Normal Protein

Diseased Protein

04

EPIC Platform

Epitope-specific antibody discovery

Our structure-based screening identifies antibodies that bind exclusively to disease- specific protein conformations —sparing normal, healthy protein conformations-for unmatched precision and safety

05

Affinity Optimization

With empirical-data-driven docking and advanced molecular dynamics simulations, we refine discovered antibodies for maximum therapeutic efficacy, stability, and manufacturability. Providing patients with safe, effective and novel therapies.

How it Works

Marrying Bottom-Up Mass Spec Surface Proteomics with Radical Labeling

Our technology goes beyond conventional approaches, unlocking critical insights that take treatment to the next level.

Learn more about the Team

Radical Labelling Techniques

High-resolution, high-throughput platform to uncover unique surface protein conformations critical for precision-targeted therapeutics.

Bottom-Up Proteomics

Ultra-sensitive and rapid analysis for high-resolution identification of disease-specific protein structures with unmatched precision.

How it Works

Marrying Bottom-Up Mass Spec Surface Proteomics with Radical Labeling

Our technology goes beyond conventional approaches, unlocking critical insights that take treatment to the next level.

Learn more about the Team

Radical Labelling Techniques

High-resolution, high-throughput platform to uncover unique surface protein conformations critical for precision-targeted therapeutics.

Bottom-Up Proteomics

Ultra-sensitive and rapid analysis for high-resolution identification of disease-specific protein structures with unmatched precision.

How it Works

Marrying Bottom-Up Mass Spec Surface Proteomics with Radical Labeling

Our technology goes beyond conventional approaches, unlocking critical insights that take treatment to the next level.

Learn more about the Team

Radical Labelling Techniques

High-resolution, high-throughput platform to uncover unique surface protein conformations critical for precision-targeted therapeutics.

Bottom-Up Proteomics

Ultra-sensitive and rapid analysis for high-resolution identification of disease-specific protein structures with unmatched precision.

Technology

About

Contact

Technology

About

Contact

Technology

About

Contact